Andrew J Gifford
Overview
Explore the profile of Andrew J Gifford including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
871
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barlow-Stewart K, Courtney E, Cowley M, Ebzery C, Fuentes Bolanos N, Gifford A, et al.
NPJ Genom Med
. 2025 Feb;
10(1):12.
PMID: 39962063
In pediatric cancer precision medicine clinical trials settings, parents proactively seeking treatment and answers to causation may request return of their child's raw data and/or biospecimen. To satisfy such requests,...
2.
Watts B, Smith C, Evans K, Gifford A, Mohamed S, Erickson S, et al.
Hemasphere
. 2025 Jan;
9(1):e70063.
PMID: 39830370
Antibody-drug conjugates (ADCs) combining monoclonal antibodies with cytotoxic payloads are a rapidly emerging class of immune-based therapeutics with the potential to improve the treatment of cancer, including children with relapse/refractory...
3.
Toscan C, McCalmont H, Ashoorzadeh A, Lin X, Fu Z, Doculara L, et al.
Blood Cancer J
. 2024 Nov;
14(1):192.
PMID: 39505850
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy that expresses high levels of the enzyme aldo-keto reductase family 1 member C3 (AKR1C3). To exploit this finding, we developed...
4.
Standley A, Xie J, Lau A, Grote L, Gifford A
Curr Protoc
. 2024 Oct;
4(10):e70021.
PMID: 39435766
The laboratory mouse has been described as a "miracle" model organism, providing a window by which we may gain an understanding of ourselves. Since the first recorded mouse experiment in...
5.
Murray J, Valli E, Milazzo G, Mayoh C, Gifford A, Fletcher J, et al.
Nat Commun
. 2024 Jul;
15(1):5585.
PMID: 38992040
MYCN oncogene amplification is frequently observed in aggressive childhood neuroblastoma. Using an unbiased large-scale mutagenesis screen in neuroblastoma-prone transgenic mice, we identify a single germline point mutation in the transcriptional...
6.
Lau L, Khuong-Quang D, Mayoh C, Wong M, Barahona P, Ajuyah P, et al.
Nat Med
. 2024 Jun;
30(7):1913-1922.
PMID: 38844796
Recent research showed that precision medicine can identify new treatment strategies for patients with childhood cancers. However, it is unclear which patients will benefit most from precision-guided treatment (PGT). Here...
7.
Evans L, Walker R, MacDiarmid J, Brahmbhatt H, Anazodo A, McCowage G, et al.
Target Oncol
. 2024 Mar;
19(3):333-342.
PMID: 38546944
Background: Recurrent or refractory solid and central nervous system (CNS) tumours in paediatric patients have limited treatment options and carry a poor prognosis. The EnGeneIC Dream Vector (EDV) is a...
8.
Gifford A
Curr Protoc
. 2023 Sep;
3(9):e891.
PMID: 37712877
Advances in genomic technologies have enabled the development of abundant mouse models of human disease, requiring accurate phenotyping to elucidate the consequences of genetic manipulation. Anatomic pathology, an important component...
9.
Mayoh C, Mao J, Xie J, Tax G, Chow S, Cadiz R, et al.
Cancer Res
. 2023 Jul;
83(16):2716-2732.
PMID: 37523146
Significance: Integrating HTS with molecular profiling is a powerful tool for expanding precision medicine to support drug treatment recommendations and broaden the therapeutic options available to high-risk pediatric cancers.
10.
Daly R, Hetherington K, Hazell E, Wadling B, Tyrrell V, Tucker K, et al.
J Pers Med
. 2023 Jul;
13(7).
PMID: 37511646
Precision medicine programs aim to utilize novel technologies to identify personalized treatments for children with cancer. Delivering these programs requires interdisciplinary efforts, yet the many groups involved are understudied. This...